Introduction
============

Atherosclerotic diseases are a major cause of morbidity and mortality worldwide. Among the classic risk factors known, elevated levels of low density lipoprotein cholesterol (LDL-C), and reduced levels of high density lipoprotein cholesterol (HDL-C) are associated with a significant increase in the incidence of atherosclerotic cardiovascular disease.

HDL are a family of heterogeneous particles that vary in size, density and chemical composition as a result of their rates of synthesis and catabolism and of continuous intravascular remodeling by the action of enzymes and transport proteins ([@b1-ijph-41-59]).

Plasma HDL concentration is modulated by both environmental and genetic factors. Findings from several studies suggest that polymorphisms at the hepatic lipase (HL), apolipoprotein AI/CIII/AIV, and cholesteryl ester transfer protein genes are major sources of genetically determined variation in plasma HDL-C concentrations ([@b2-ijph-41-59]). Notably, allelic variations at the HL gene account for up to 25% of the variability in plasma HDL-C concentrations ([@b2-ijph-41-59]).

Hepatic Lipase (HL), a glycoprotein member of the lipase super family, plays an important role in the metabolism and modeling of both pro-and anti atherogenic lipoproteins. Synthesized and secreted by the liver, HL carries out several metabolic functions, including the hydrolysis of triglycerides, the lipolysis of phospholipids, the modeling of small, dense atherogenic LDL particles, and the catabolism of HDL ([@b3-ijph-41-59]).

The human hepatic lipase gene (LIPC), located on chromosome 15q21, and is 35kb in size, with 9 exons spans \>120 kb of DNA and encodes a protein with 449 amino acids ([@b4-ijph-41-59]).

The C→T base pair substitution at Position-514 is associated with up to 30% reduction in promoter activity in vitro ([@b5-ijph-41-59]--[@b7-ijph-41-59]), marked decreased plasma HL activity, and increased concentrations of plasma HDL, HDL2, and large buoyant LDL particles. The association between −514C/T polymorphisms in LIPC gene with the serum HDL-C levels was demonstrated. ([@b8-ijph-41-59]--[@b10-ijph-41-59]).

Thus, there is considerable evidence of associations between promoter polymorphisms of the HL gene and HL activity and plasma lipoprotein concentrations. The C-514T polymorphism of LIPC gene is not associated with CHD susceptibility ([@b11-ijph-41-59]). However, the effects of the LIPC genotype on atherosclerosis have been controversial ([@b12-ijph-41-59]).

With this background, the present study investigated the effects of LIPC promoter −514 C→T polymorphism on coronary atherosclerosis inpatients in Tabriz city in Iran.

Materials and Methods
=====================

Subjects
--------

A total of 342 unrelated patients with possible coronary heart stenosis ages 17--80 years (mean 54 years) attending the specialist clinics at the Emam Reza and Shahid madani hospitals in Tabriz, Iran were studied. All subjects underwent coronary angiography. The coronary angiograms were classified as non CAD, stenosis of one vessel (1VD), 2 vessels (2VD) and 3 vessels (3VD).

Data for body mass index (BMI), smoking history, blood pressure, diabetes status and lipid profile were collected. Hypertension was considered to be present if systolic blood pressure was \>140 mmHg or diastolic blood pressure \>90 mmHg and any antihypertensive treatment had been instituted. Diabetes mellitus was diagnosed if fasting plasma glucose was \>120 mg/dl. Smoking status was defined as non-smokers, low smokers (\<10 cigarettes/day), and ex smoker (\> 10 cigarettes/day).

The inclusion criteria were the presence of chest pain whose required angiographic examination. Those of receiving lipid lowering drugs or having a history of coronary bypass surgery, diabetes, hepatic or renal failure (serum creatinine \> 2.0 mg/dl) and uncontrolled hypothyroidism, or neoplasias were excluded from the study.

Informed consent was obtained from patients and the study was approved by the Tabriz University of Medical Sciences Ethical Committee.

Blood sampling and biochemical determinations
---------------------------------------------

Blood samples were collected early in the morning after an overnight fast in glass tubes. Glucose, total cholesterol (TC), triglycerides (TG), HDL-C (direct method) and LDL-C (direct method) were determined by standard enzymatic procedures using commercial kits (Pars Azmon Co). Apolipoprotein A1 (Apo A1) and Apolipoprotein B (Apo B) levels were measured by immunoturbidimeteric method (Pars Azmon Co). Creatinine is measured with Jaffe method for exclude renal patients.

Genotyping of hepatic lipase gene polymorphism
----------------------------------------------

DNA was extracted from 1 ml EDTA-containing blood using phenol-chlorophorm method. Amplification of a 711-bp promoter region of the hepatic lipase gene was carried out by polymerase chain reaction (PCR) with 50 ng genomic DNA and 10 pmol of each oligonucleotide primers (F: 5′-GGATCACCTCTCAATGGGTC -3′, and R: 5′-ACCTGGTTTCAGGCTTTGTC-3′) in 25 μl. PCR was performed at 96 °C for 5 min followed by 36 cycles of denaturation at 95 °C for 45 sec, annealing at 60 °C for 1 min, and extension at 72 °C for 1 min.

The PCR products (10 μl) were then digested with 5 units of restriction enzyme NlaIII in a total volume of 20 μl as recommended by the manufacture (Fermentas canada). Digested products were separated by electrophoresis on a 6% non-denaturing polyacrylamide gel at 200 V for 2 h. and visualized by silver staining procedure ([Fig. 1](#f1-ijph-41-59){ref-type="fig"}).

Statistical analysis
--------------------

Frequency distributions of characteristics of studied subjects were examined according to LIPC genotype. Chi-square tests were used to compare the genotypes. Due to small number of TT genotype (n =17) and absence of any significant differences between CT and TT genotypes regarding HDL-C concentrations, we considered CT and TT genotype as a group.

All values are expressed as means ± S.D. unless otherwise noted. ANOVA was used to analyze the differences in plasma lipid, ApoA and ApoB levels. When statistically significant effects were demonstrated, Turkey's post-hoc test was used to identify between-group differences. In order to adjust for sex, age, hypertension, BMI and smoking, we employed a general linear model.

Statistical analyses were carried out using the SPSS statistical package (SPSS, 11.5). Statistical significance was assessed at the 5% level of probability.

Results
=======

A total of 342 subjects were investigated, from which 196 individuals were found to be affected with CAD based on coronary angiography procedure. Among the all subjects, 222 carriers of the CC genotype, 103 of the CT genotype and 17 of the TT genotype of the LIPC promoter gene were identified. This study revealed a T allele frequency of 0.221 and 0.150 in males and females respectively ([Table 1](#t1-ijph-41-59){ref-type="table"}). The interaction between LIPC genotypes and CAD groups is represented in [Table 2](#t2-ijph-41-59){ref-type="table"}.

Statistical analysis failed to show any overall relationship between the −514C/T polymorphisms and CAD groups. Also values of the CAD groups were similar among the 3 genotype groups.

The characteristics of the subjects according to the --514C/T polymorphism are shown in [Table 3](#t3-ijph-41-59){ref-type="table"}. To investigate the effects LIPC promoter polymorphisms on lipid profile, we compared two subgroups LIPC genotype CC compared with genotype CT/TT.

No significant differences were found between subjects with the CC genotype and those with the CT/TT genotype concerning total cholesterol, triglyceride, ApoA1.ApoB, LDL-C, BMI, and age. Finally, a significant association was found between T allele and HDL-C concentration in men group ([Table 4](#t4-ijph-41-59){ref-type="table"}).

Discussion
==========

The present study investigated the effects of −514 C→T, LIPC polymorphism on lipid profile in subjects with coronary arteries stenosis. This polymorphism was detected in about 36% of patients with angiographically established coronary artery disease and in about 33% of non CAD control subjects ([Table 1](#t1-ijph-41-59){ref-type="table"}).

This study revealed a T allele frequency of 0.226, 0.136 and 0.223, 0.170 for non CAD (males and females) and CAD (males and females) respectively. These finding are in agreement with previously reported T allele frequency in Caucasians ([@b13-ijph-41-59], [@b14-ijph-41-59]).

It has been suggested that HL may modulate the development of cardiovascular disease through its catalytic activity and independently of ligand-binding function pathways ([@b15-ijph-41-59]). In addition, HL has been identified to be present in the vessel wall where it modulates atherogenic risk in apoE-deficient and lecithin-cholesterol acyl transferase transgenic mice ([@b16-ijph-41-59]). These multiple functions of HL, which facilitate not only plasma lipid metabolism but also cellular lipid uptake, can be anticipated to have a major and complex impact on atherogenesis. Therefore, the C-514T HL polymorphism may confer atherosclerosis susceptibility by affecting HL synthesis and activity. However, no significant difference was founded concerning T allele frequency in non CAD and CAD groups in this study (*P*=0.752 and *P*= 0.466 for women and men respectively). There is ample evidence to demonstrate that HL affects both HDL cholesterol and triglyceride-rich lipoproteins ([@b17-ijph-41-59], [@b18-ijph-41-59]). It can be postulated that TT genotype with low HL activity could changed production of preβ HDL and delivery of HDL -C to the liver ([@b19-ijph-41-59]). We didn't find any statistical significance in other heart risk factors in CC and CT&TT genotype in our study groups, therefore we suggest substitution C→T in −514 of LIPC don't change the heart risk factors ([Table 3](#t3-ijph-41-59){ref-type="table"}). Very few data are available concerning the relation between the LIPC −514C→T polymorphism and plasma HDL-C concentrations among patients with coronary artery stenosis.

In this study, serum HDL-C concentration was found to be higher among men subjects with T allele ([Table 4](#t4-ijph-41-59){ref-type="table"}). These findings are in consistent with literature documenting elevated plasma HDL-cholesterol concentration in association with the T allele among the general white population ([@b20-ijph-41-59]--[@b23-ijph-41-59]).

It has been widely accepted that such an association is likely to be mediated by a reduction in HL activity induced by the- 514 T allele. In vitro studies reported upto30% reduction in promoter activity attributed to the C→T base substitution ([@b24-ijph-41-59], [@b25-ijph-41-59]). The role of HL in the metabolism of HDL is well recognized ([@b9-ijph-41-59]). The association of T allele with HDL-C levels in a specific Gender may be due to differences in sex hormones which may differentially modulate lipoprotein metabolism or HL activity between males and females. The gender difference in HL activity has led some to hypothesize that HL activity is a major determinant of the more atherogenic. Lipoprotein profile in men compared with women. Moreover As HL activity is regulated by sex- steroid hormones which are presented in higher level in men than in women, the −514C→T of LIPC gene may cause further reduction of HL activity in men, leading to denser HDL-C concentration ([Table 4](#t4-ijph-41-59){ref-type="table"}).

In conclusion, these data demonstrate two findings. First, there was a significant association of T allele with HDL-C concentration in men groups and second there was no difference at T allele frequency in non CAD and CAD groups.
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![Representative polyacrylamide gel electrophoresis picture of −514C/T. Lane 1 is DNA marker, lane2 and 5 and 6 and 10 are related to the CC genotype, lane3 and 8 and 9 are related to the CT genotype, lane 4 and 7 are related to the TT genotype. Lane 11 is negative control (without DNA), Lane 12 is DNA control (without enzyme)](ijph-41-59f1){#f1-ijph-41-59}

###### 

Genotype distribution and allele frequency of −514 C \>T polymorphism between male and female groups

  **Genotype**   **% Frequency (number)**            
  -------------- -------------------------- -------- -----------
  CC             62.4(151)                  71(71)   64.9(222)
  CT             31(75)                     28(28)   30.1(103)
  TT             6.6(16)                    1(1)     5(17)
  T allele       0.221                      0.150    0.211

###### 

Characteristics of the subjects according to LIPC genotype and CAD status

  **Genotype**                                         **non CAD**                                          **1VD**   **2VD**   **3VD**   **Total**
  ---------------------------------------------------- ---------------------------------------------------- --------- --------- --------- -----------
  Female [\*](#tfn1-ijph-41-59){ref-type="table-fn"}                                                                                      
                                                                                                                                          
  CC                                                   43                                                   11        9         8         71
  CT                                                   16                                                   4         4         4         28
  TT                                                   0                                                    1         0         0         1
  Total                                                59                                                   16        13        12        100
                                                       Male [\*\*](#tfn2-ijph-41-59){ref-type="table-fn"}                                 
  CC                                                   55                                                   27        35        34        151
  CT                                                   25                                                   21        15        14        75
  TT                                                   7                                                    1         2         6         16
  Total                                                87                                                   49        52        54        242

*P* Value is 0.752

*P* Value is 0.466

CAD; coronary artery disease, 1VD; stenosis of one vessel, 2VD; stenosis of 2 vessels, 3VD; stenosis of 3 vessels.

*P*\< 0.05 is significant

###### 

Characteristics of the subjects according to LIPC genotype status

  **Parameter**                 **CC(n=222)**   **CT&TT(n=120)**   ***P*** **Value**
  ----------------------------- --------------- ------------------ -------------------
  Age\[ year\]                  53.2±10.7       54.7±10.0          0.25
  BMI \[kg/m^2^\]               27.0±4.0        26.7±3.8           0.58
  Apo A-I \[mg/dl\]             123.6±19.0      124.1±21.4         0.84
  Apo B~100~ \[mg/dl\]          103.7±26.5      103.3±3            0.90
  Total Cholesterol \[mg/dl\]   172.7±40.9      177.2±50.1         0.43
  Triglyceride \[mg/dl\]        196.9±100.9     174.1±94.8         0.07
  HDL-C \[mg/dl\]               36.3±9.6        39.3±12.1          0.02
  LDL-C \[mg/dl\]               95.1±33.3       96.6±35.1          0.73

*P*\< 0.05 is significant

BMI, Body Mass Index; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein cholesterol, Apo A-I; Apolipoprotein A-I, Apo B~100~; Apolipoprotein B~100~

###### 

HDL-C concentration in subjects according to LIPC genotype status and gender

  **HDL-C(mg/dl)**   **−514C/T**   **n**        **Mean**± SD   ***P*** **Value**
  ------------------ ------------- ------------ -------------- -------------------
  Male               CC            151          34.8±9.1       0.01
  CT&TT              91            38.61±10.8                  
  Female             CC            71           39.7±10.0      0.54
  CT&TT              29            41.5±15.6                   
  Total              CC            222          36.3±9.6       0.02
  CT&TT              120           39.3±12.2                   

*P*\< 0.05 is significant
